NCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
28 trialsNCT04396860 2026-03-05
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02498600 2025-08-29
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02397720 2025-06-08
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03472586 2025-04-24
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Thomas Jefferson University
Phase 2 Completed
NCT02428192 2025-02-25
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01919619 2024-12-03
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02027935 2024-10-08
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01585194 2024-07-09
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02107755 2024-05-21
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02519322 2024-04-05
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03749460 2023-12-29
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Phase 1/2 Completed
NCT04118166 2023-12-12
Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Stanford University
Phase 2 Completed
NCT02304458 2023-10-17
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02500797 2023-10-17
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT03222076 2023-07-10
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03396952 2022-10-13
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01498978 2020-10-14
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01473940 2020-03-06
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Northwestern University
Phase 1 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT02254772 2019-11-27
A Phase I/II Study of Intratumoral Injection of SD-101
Stanford University
Phase 1/2 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed